Navigation Links
Doyle Raizner Pradaxa Case Chosen for Bellwether Early Trial Consideration
Date:7/30/2013

(PRWEB) July 30, 2013

As progress continues in the Pradaxa multi district litigation (MDL), the bellwether case selection process has concluded with one of Doyle Raizner’s cases being chosen. Doyle Raizner’s case is one of 16 cases out of approximately 871 currently pending cases that were selected to move into the bellwether case-specific discovery phase. After the conclusion of case-specific discovery, Presiding Judge David Herndon will select four of the 16 cases to proceed to trial on August 11, 2014, November 3, 2014, January 5, 2015, and February 16, 2015. Judge Herndon’s selection of the four trial cases will occur on or before November 22, 2013.

Bellwether case selection is a judicial procedure where a select group of cases are presented for determining core issues, such as liability and damages, for the remaining cases. The outcome of the bellwether trials typically assists in the resolution of all cases within multi-district litigation. They also assist in expediting the trial process. In the case of Pradaxa litigation Judge Herndon promised an expedited process due to the age of the plaintiffs, among other factors.

“The patient whose case was selected for the bellwether selection suffered a near fatal episode of gastrointestinal bleeding just two weeks after her initial dose of Pradaxa,” said Patrick Dennis, the Doyle Raizner partner who manages the firm’s pharmaceutical docket.

Pradaxa litigation was consolidated into a MDL in August 2012 in the Southern District of Illinois, a federal court. [Docket No. 3:13-cv-50028-DRH-SCW] The court will handle claims that the blood thinner, Pradaxa, has serious and often deadly adverse side effects, including an increased risk of gastrointestinal and other bleeds, which were not properly communicated by Boehringer Ingelheim to healthcare professionals or patients. The drug is often prescribed to elderly patients to reduce the risk of stroke in people with atrial fibrillation. Compounding, a possible internal bleeding risk is the lack of an antidote to stop Pradaxa’s internal bleeding side effect. No antidote exists because Pradaxa was rushed to market before Boehringer Ingelheim took efforts to develop an antidote to protect patients taking this drug. As a result, many takers of Pradaxa have suffered from hemorrhages and deaths. The large number of complaints and impending personal injury cases against Pradaxa moved it to the top of 2011’s most dangerous drug report issued by the Institute for Safe Medication Practices, January 12, 2012.

To learn more about the firm and their part in Pradaxa litigation, please visit http://www.PradaxaLitigation.com.

About Doyle Raizner LLP:

Doyle Raizner LLP is a national personal injury litigation firm with main offices in Houston, Texas and Phoenix, Arizona. The firm's attorneys specialize in helping victims’ secure fair compensation for injuries or the death of a loved one.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937550.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Bleeding Litigation
2. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
3. Pradaxa Lawsuit Attorneys at Wright & Schulte LLC Report on Scheduling of Bellwether Trials in Federal Pradaxa Bleeding Lawsuits
4. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
5. New Lawsuit on Pradaxa Bleeding: Now, AttorneyOne Can Provide Advice
6. New Study Casts Doubt on FDA Pradaxa Conclusions
7. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Side Effects Litigation
8. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Pradaxa Bleeding Claims Pending in Federal Litigation Now Exceed 1,000
9. Latest Pradaxa Internal Bleeding Problem Allegation Lawsuits Update; Resource4thePeople Reports Judge Schedules Important Hearing
10. New Lawsuit on Alleged Pradaxa Wrongful Death: Now, AttorneyOne Can Provide Advice
11. Pradaxa Lawsuits Move Ahead As Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... in Beverly Hills, California, will be included in the 2016 “Guide to America’s ... exceptional professionals based on the amalgamation of their education, experience, and professional associations. ...
(Date:12/2/2016)... Wilmington, Delaware (PRWEB) , ... December 02, 2016 ... ... has released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite ... from sample entry through labeling, storing, shipping and disposal. The new version is ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... , ... "Pro3rd Accents Volume 2 is a set of 30 accented lower ... just a few clicks of the mouse," said Christina Austin - CEO of Pixel ... from various styles with accented animations, rigid boxes, simplistic lines, and more. In Addition, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to build intelligent, connected applications, was named the best Sales Team of 2016 ... winner announcement was made today by the Software & Information Industry Association (SIIA), ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... , Dec. 3, 2016  Findings from a ... of CTL019, an investigational chimeric antigen receptor T ... and young adult patients with B-cell acute lymphoblastic ... oral session at the 58th American Society of ... 4:00-5:30 p.m.). The global Phase II study found ...
(Date:12/2/2016)... -- Persistence Market Research (PMR) delivers key ... titled, "Global Market Study on Cardiac Pacemaker: North America Regional ... 2016 and 2024". The global cardiac pacemaker market was valued ... likely to decline to US$ 3923.8 Mn by 2024. ... is anticipated to exhibit a declining CAGR of -0.5% ...
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
Breaking Medicine Technology: